Sitagliptin Response Study
(PRS Trial)

Recruiting in Palo Alto (17 mi)

Overseen bySimeon I Taylor, MD, PhD

Age: 18+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Phase 4

Waitlist Available

Sponsor: University of Maryland, Baltimore

Prior Safety Data

Trial Summary

What is the purpose of this trial?

This is a research study to find out how different people respond to a medication called sitagliptin. Sitagliptin is an FDA approved medication that is used to treat diabetes. We are asking for healthy, non-diabetic volunteers to participate in this 7-week study. If you agree to participate, you will take part in 2 clinic visits that are 4-6 weeks apart. At the clinic visits you will have an oral glucose tolerance test (OGTT) and other blood tests to see how your body processes glucose (sugar). An OGTT is a test in which your drink glucose and then blood samples are taken afterward at specific time points to measure glucose and insulin in your blood. Each clinic visit will last about 5 hours.

Eligibility Criteria

This study is seeking healthy, non-diabetic volunteers to understand how different people react to the diabetes medication sitagliptin. Participants will be involved in two clinic visits for testing over a span of 7 weeks.

Inclusion Criteria

I am older than 18.

Members of Old Order Amish community in Lancaster, PA

Exclusion Criteria

I am not on medications that would affect sitagliptin treatment.

I am not pregnant or will be tested for pregnancy before treatment.

Anemia: hematocrit < 35%

See 5 more

Treatment Details

Interventions

Oral Glucose Tolerance Test (Other)

Trial OverviewThe trial is examining how individuals process sugar after taking sitagliptin by using an Oral Glucose Tolerance Test (OGTT), where participants drink glucose and have their blood tested at intervals to measure sugar and insulin levels.

Participant Groups

2Treatment groups

Experimental Treatment

Placebo Group

Group I: SitagliptinExperimental Treatment1 Intervention

Sitagliptin 100 mg given 2 hours prior to the oral glucose tolerance test

Group II: PlaceboPlacebo Group1 Intervention

Placebo given 2 hours prior to the oral glucose tolerance test